Relevance of new scientific information (Santos - Vigil et al ., 2018 1 ) in relation to the risk assessment of genetically mo dified crops with Cry1Ac
The following is a study detailing the safety of GMO crops.
The EFSA GMO Panel assessed the safety of Cry1Ac protein in the context of various GM plants applications (Table 1). It is noted that the EFSA GMO Panel assessed different variants of the Cry1Ac proteins, all fully characterised in structure and function, and did not identify concerns regarding the safety of any of them. In particular, the allergenicity assessmentof all Cry1Acprotein varietns was performed in line with the principles described in Codex Alimentarius guidelines on biotechnology (2003-2009), the EFSA GMO Panel guidance document for food/feed safety (2011) and Regulation (EU) 503/2013. For such assessment, the EFSA GMO Panel followed a weight-of-evidence approach considering information of different nature. This included indications of safety concern from the donor organism and/or from thenewly expressed protein itself,as well as bioinformatics analysessearching for relevant similarities with known allergens and in vitro degradation studies. In the context of the GM plants evaluated (Table 1), the EFSA GMO Panel identified no indications of safety concerns regarding allergenicity.